SCHEMBL810351

SCHEMBL810351

CC(C)(O)c1ccc2c(Nc3cc(OCc4ccc(Br)cc4)ccc3Sc3ccc(O)cc3)ncnc2n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.61
AKT2 P31751 1/20 0.61
KDR P35968 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 1/20 0.36
EGFR P00533 6/20 0.35
ERBB2 P04626 2/20 0.35
PDGFRB P09619 2/20 0.33
HDAC3 O15379 1/20 0.33
ABL1 P00519 1/20 0.33
CDK2 P24941 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL810849 0.90 PIM1 (0.55) PIM1AKT2KDRMEN1KMT2A
SCHEMBL810522 0.89 PIM1 (0.77) PIM1AKT2KDRMEN1KMT2A
SCHEMBL810039 0.86 PIM1 (0.62) PIM1AKT2KDRMEN1KMT2A
SCHEMBL811069 0.86 PIM1 (0.64) PIM1AKT2KDRMEN1KMT2A
SCHEMBL810869 0.86 PIM1 (0.61) PIM1AKT2KDRMEN1KMT2A
SCHEMBL810073 0.85 PIM1 (0.55) PIM1AKT2KDRMEN1KMT2A
SCHEMBL810758 0.84 PIM1 (0.65) PIM1AKT2KDRMEN1KMT2A
SCHEMBL811361 0.83 PIM1 (0.59) PIM1AKT2KDRMEN1KMT2A
SCHEMBL809987 0.82 PIM1 (0.63) PIM1AKT2KDRMEN1KMT2A
SCHEMBL810803 0.82 PIM1 (0.69) PIM1AKT2KDRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885KDR 3293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.